1Scandinavian Simvastatin SurvivalStudy Group. Randomised trial of cholesterol lowering in 4 444 patients with coronaryheart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344: 1383～1389
2Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol.Lancet, 1996, Oct, 19:348:1079～1082
3Wheeler DC. Are there potential non-lipid-lowering use of statins? Drugs, 1998,Oct, 56(4):517～522
4Kearney D, Fitzgerald D. The anti-thrombotic effect of statins. J Am Coll Cardial,1999, Apr, 33(5):1305～1307
5Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implicationsfor cardiovascular event reduction. JAMA, 1998, 279:1643～1650
6Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis andplatelet function by simvastatin in type Ⅱα hyper cholesterolaemia. Arterioscler TrombVasc Biol, 1995, 15: 247～251
7Alfon J, Pueyo Palazon C, Royo T, et al. Effects of statins in thrombosis andaortic lesion development in a dyslipemic rabbit model. Thromb Haemost, 1999, May,81(5):822～827
8Aoki I, Aoki N, Kawano K, et al. Platelet-dependent thrombin generation in patientswith byperlipidaemia. J Am Coll Cardiol, 1997, 30:91～96
9Szczeklik A, Musial J, Undas A, et al. Inhibition of thrombin gereration bysimvastatin and lack of additive effect of aspirin in patients with markedhypercholesterolemia. J Am Coll Cardiol, 1999, 33: 1286～1293
10Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, Creactiveprotein, albumin, or leukocyte count with coronary heart disease:meta-analyses ofprospective studies. JAMA, 1998, 279:1477～1482
5Rosenson RS,Tangney CC.Antiatherothrombotic properties of statins:implications for cardiovascular event reduction[J].JAMA,1998,279(20):1643-1650.
6Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a predictive factor against coronary heart disease.The Framingham Study. Am J Med, 1997, 62: 707- 14.
